Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications

Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications

The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications

Inclusion Criteria:

• Adult (>18 years)
• Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route
• Naïve to long-term inhaled bronchodilator therapy
• High risk of post-operative pulmonary complications (Pre-operative FEV1 < 80%)

Exclusion Criteria:

• Patient refusal
• Pregnancy
• Emergency surgery
• Patient with a physiological status of WHO IV or ASA ≥ IV
• Asthma
• Patients treated with long-acting bronchodilators
• Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction < 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke < 3 months
• High-grade unresponsive conductive disorders or unstable arrhythmia
• Thyrotoxicosis, pheochromocytoma
• Unbalanced diabetes
• Hypersensitivity to ß-2 mimetics or lactose
• Current participation in a trial of another drug therapy